ArticleJHEP reports : innovation in hepatology2020

Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis.

Pinelopi Arvaniti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.